Welcome to our dedicated page for Aprea Therapeutics news (Ticker: APRE), a resource for investors and traders seeking the latest updates and insights on Aprea Therapeutics stock.
Aprea Therapeutics, Inc. reports developments as a clinical-stage precision medicine oncology company developing targeted therapies for patients with biomarker-defined cancers. Its updates center on small-molecule programs designed to exploit cancer-specific genetic vulnerabilities, including APR-1051, an oral WEE1 kinase inhibitor, and ATRN-119, a small-molecule ATR inhibitor, for solid tumor indications.
Recurring news themes include clinical activity from the ACESOT-1051 study of APR-1051, oncology conference presentations, pipeline and corporate updates, financial results, and financing activity supporting research and development. Company communications also describe biomarker-guided development, safety and tolerability observations, and capital actions tied to its clinical-stage oncology strategy.
Aprea Therapeutics (Nasdaq: APRE) reported first quarter 2026 results and a corporate update. An oversubscribed $30 million private placement closed March 31, boosting cash and cash equivalents to $46.5 million and extending the anticipated cash runway into Q1 2028.
In Phase 1 trial ACESOT-1051 of WEE1 inhibitor APR-1051, 2 partial responses and 6 stable disease cases have been observed among 28 treated patients, with favorable tolerability. Aprea plans to expand enrollment to at least 50 uterine serous carcinoma patients and additional ovarian cancer patients.
ATR inhibitor ATRN-119 in trial ABOYA-119 was paused as Aprea evaluates combination strategies. Q1 2026 operating loss was $3.4 million and net loss was $3.3 million ($0.22 per share), both improved versus Q1 2025.
CatalYm (NASDAQ: APRE) appointed Christian S. Schade as Chairman of the Board effective April 28, 2026.
The company is advancing its lead GDF-15 inhibitor, visugromab, with four late-stage clinical studies ongoing. Mr. Schade brings 30+ years of biotech leadership, most recently leading Halda Therapeutics into a $3.05 billion acquisition in December 2025, and previously served as CEO and chairman of Aprea (2016–2022; chairman 2020–2023).
Aprea Therapeutics (Nasdaq: APRE) announced acceptance of an abstract reporting early results from the first-in-human Phase 1 ACESOT-1051 study of WEE1 inhibitor APR-1051 for advanced solid tumors at the ASCO 2026 Annual Meeting, May 29–June 2, 2026 in Chicago.
The poster presentation (Board 244) is scheduled for May 30, 2026, 1:30 PM–4:30 PM CDT, with presenting author Shiraj Sen, MD, PhD. Trial identifier: ClinicalTrials.gov NCT06260514.
Frazier Life Sciences (APRE) appointed Christian Schade as Senior Advisor, based in its Boston office, to support portfolio companies on corporate strategy and business development.
Schade brings 30+ years of biopharma experience, including CEO roles, prior leadership at Aprea Therapeutics (Nasdaq: APRE), and involvement in multiple acquisitions and an IPO.
Aprea Therapeutics (Nasdaq: APRE) closed an oversubscribed private placement, raising approximately $30 million in gross proceeds on March 31, 2026. The financing included pre-funded warrants to purchase ~37.2 million shares and warrants for ~37.2 million shares with a $0.683 exercise price expiring Dec 31, 2029.
The company said it will use net proceeds for general corporate purposes and R&D to support APR-1051 development, expand the ACESOT-1051 study, and enroll at least 50 patients in uterine serous carcinoma and cyclin E-overexpressing platinum-resistant ovarian cancer cohorts.
Aprea Therapeutics (Nasdaq: APRE) announced an oversubscribed private placement expected to raise approximately $30 million in gross proceeds before fees. The financing includes pre-funded warrants to buy ~37.2 million shares and warrants to purchase an additional ~37.2 million shares with a $0.683 strike.
The company expects to close on or about March 31, 2026, use proceeds for general corporate and R&D purposes, and believes the funds will extend cash runway into Q1 2028. Dose escalation completion for ACESOT-1051 is anticipated in Q2 2027.
Aprea (Nasdaq: APRE) reported a confirmed partial response (PR) to WEE1 inhibitor APR-1051 in the Phase 1 ACESOT-1051 trial at the 220 mg once-daily dose.
The patient with PPP2R1A-mutated endometrial cancer had a 50% reduction in target lesion size at first scan, a further 9.5% reduction at confirmation, and CA-125 fell from 362 U/mL to 40.2 U/mL. To date 24 patients received 10–220 mg; two PRs (one confirmed) and five stable disease responses reported. Dose escalation will progress toward 300 mg once daily in Q2 2026.
Aprea Therapeutics (Nasdaq: APRE) reported Q4 and full-year 2025 results and a corporate update on March 16, 2026. Key clinical progress includes two unconfirmed partial responses to oral WEE1 inhibitor APR-1051 in PPP2R1A-mutated endometrial cancer at 150 mg and 220 mg dose levels with marked CA-125 declines. ATRN-119 RP2D set at 1,100 mg while monotherapy enrollment is paused pending combination studies. Financials: cash of $14.6M (12/31/25), successful private placements raising ~$8.7M, Q4 net loss $2.5M ($0.32/share), 2025 net loss $12.6M ($1.93/share). Company expects cash runway into Q1 2027.
Aprea Therapeutics (Nasdaq: APRE) reported a second unconfirmed partial response in its Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051, observed at the 220 mg dose. The patient had a 50% target lesion reduction and an 87% drop in CA-125, with only Grade 1 adverse events.
To date, 22 patients have been treated across 10–220 mg. Both unconfirmed partial responses occurred in endometrial cancer with PPP2R1A mutations; confirmation and an additional trial update are expected in Q2 2026.
Aprea Therapeutics (Nasdaq: APRE) announced that Oren Gilad, Ph.D., President and CEO, will present a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 at 8:40 am EST. The presentation is virtual and will be webcast.
The webcast will be available for 90 days via the conference link or Aprea's Investors "News & Events" page. Investors may request 1:1 meetings through their Oppenheimer representative.